Lantern Net Debt vs Current Deferred Revenue Analysis

LTRN Stock

USD 6.33 0.14 2.26%

Lantern Pharma financial indicator trend analysis is infinitely more than just investigating Lantern Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lantern Pharma is a good investment. Please check the relationship between Lantern Pharma Net Debt and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lantern Pharma Net Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have very week relationship.

The correlation between Lantern Pharma's Net Debt and Current Deferred Revenue is 0.29. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Lantern Pharma, assuming nothing else is changed. The correlation between historical values of Lantern Pharma's Net Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Lantern Pharma are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Debt i.e., Lantern Pharma's Net Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.29

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Lantern Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.As of the 16th of May 2024, Selling General Administrative is likely to drop to 5,684. In addition to that, Issuance Of Capital Stock is likely to drop to 0.00

Lantern Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.39	0.92	1.0	0.98	0.79	-0.99	-0.79	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.86	0.39	0.91
Other Current Liab	0.39		0.54	0.38	0.49	0.85	-0.29	-0.84	0.53	0.31	0.22	0.06	0.39	-0.55	0.56	0.72	0.53	0.54	0.38	0.39	-0.54	0.39	-0.55	0.22	-0.32	0.31
Total Current Liabilities	0.92	0.54		0.92	0.95	0.82	-0.85	-0.88	0.98	0.85	0.59	-0.11	0.92	-0.8	0.99	0.92	0.97	1.0	0.92	0.92	-0.8	0.92	-0.8	0.68	0.14	0.87
Total Stockholder Equity	1.0	0.38	0.92		0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Net Tangible Assets	0.98	0.49	0.95	0.98		0.84	-0.94	-0.84	0.97	0.94	0.76	0.02	0.98	-0.89	0.97	0.93	0.99	0.96	0.98	0.98	-0.88	0.98	-0.89	0.81	0.31	0.86
Property Plant And Equipment Net	0.79	0.85	0.82	0.79	0.84		-0.73	-0.93	0.82	0.74	0.67	0.03	0.79	-0.8	0.87	0.94	0.85	0.83	0.79	0.79	-0.78	0.79	-0.8	0.69	0.14	0.64
Net Debt	-0.99	-0.29	-0.85	-0.99	-0.94	-0.73		0.71	-0.89	-1.0	-0.82	-0.07	-0.99	0.89	-0.89	-0.86	-0.93	-0.86	-0.99	-0.99	0.87	-0.99	0.89	-0.88	-0.45	-0.9
Retained Earnings	-0.79	-0.84	-0.88	-0.78	-0.84	-0.93	0.71		-0.89	-0.72	-0.45	-0.08	-0.78	0.85	-0.89	-0.96	-0.88	-0.89	-0.78	-0.79	0.83	-0.78	0.84	-0.51	0.15	-0.76
Accounts Payable	0.94	0.53	0.98	0.94	0.97	0.82	-0.89	-0.89		0.89	0.62	0.08	0.94	-0.87	0.98	0.95	0.99	0.98	0.94	0.95	-0.84	0.94	-0.87	0.69	0.13	0.91
Cash	0.99	0.31	0.85	0.99	0.94	0.74	-1.0	-0.72	0.89		0.82	0.07	0.99	-0.89	0.9	0.87	0.93	0.86	0.99	0.99	-0.88	0.99	-0.89	0.88	0.45	0.9
Non Current Assets Total	0.8	0.22	0.59	0.8	0.76	0.67	-0.82	-0.45	0.62	0.82		0.13	0.8	-0.61	0.69	0.65	0.7	0.6	0.8	0.79	-0.57	0.8	-0.61	0.98	0.79	0.52
Non Currrent Assets Other	0.03	0.06	-0.11	0.03	0.02	0.03	-0.07	-0.08	0.08	0.07	0.13		0.03	-0.18	-0.04	0.06	0.04	-0.09	0.03	0.03	-0.01	0.03	-0.19	0.0	-0.1	0.04
Cash And Short Term Investments	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03		-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Common Stock Total Equity	-0.89	-0.55	-0.8	-0.89	-0.89	-0.8	0.89	0.85	-0.87	-0.89	-0.61	-0.18	-0.89		-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89	1.0	-0.66	-0.08	-0.86
Common Stock Shares Outstanding	0.95	0.56	0.99	0.95	0.97	0.87	-0.89	-0.89	0.98	0.9	0.69	-0.04	0.95	-0.83		0.95	0.98	0.99	0.95	0.95	-0.82	0.95	-0.83	0.76	0.23	0.87
Capital Surpluse	0.92	0.72	0.92	0.91	0.93	0.94	-0.86	-0.96	0.95	0.87	0.65	0.06	0.91	-0.91	0.95		0.96	0.93	0.91	0.92	-0.9	0.91	-0.91	0.7	0.09	0.86
Other Stockholder Equity	0.97	0.53	0.97	0.97	0.99	0.85	-0.93	-0.88	0.99	0.93	0.7	0.04	0.97	-0.91	0.98	0.96		0.98	0.97	0.97	-0.89	0.97	-0.91	0.76	0.22	0.9
Total Liab	0.93	0.54	1.0	0.92	0.96	0.83	-0.86	-0.89	0.98	0.86	0.6	-0.09	0.93	-0.82	0.99	0.93	0.98		0.92	0.93	-0.82	0.93	-0.82	0.69	0.14	0.88
Net Invested Capital	1.0	0.38	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92		1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Total Current Assets	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.79	0.95	0.99	0.79	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0		-0.88	1.0	-0.89	0.86	0.38	0.91
Capital Stock	-0.88	-0.54	-0.8	-0.88	-0.88	-0.78	0.87	0.83	-0.84	-0.88	-0.57	-0.01	-0.88	0.98	-0.82	-0.9	-0.89	-0.82	-0.88	-0.88		-0.88	0.98	-0.65	-0.09	-0.85
Net Working Capital	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88		-0.89	0.86	0.39	0.91
Common Stock	-0.89	-0.55	-0.8	-0.89	-0.89	-0.8	0.89	0.84	-0.87	-0.89	-0.61	-0.19	-0.89	1.0	-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89		-0.66	-0.09	-0.86
Property Plant Equipment	0.86	0.22	0.68	0.87	0.81	0.69	-0.88	-0.51	0.69	0.88	0.98	0.0	0.87	-0.66	0.76	0.7	0.76	0.69	0.87	0.86	-0.65	0.86	-0.66		0.77	0.62
Other Assets	0.39	-0.32	0.14	0.39	0.31	0.14	-0.45	0.15	0.13	0.45	0.79	-0.1	0.39	-0.08	0.23	0.09	0.22	0.14	0.39	0.38	-0.09	0.39	-0.09	0.77		0.09
Other Current Assets	0.91	0.31	0.87	0.91	0.86	0.64	-0.9	-0.76	0.91	0.9	0.52	0.04	0.91	-0.86	0.87	0.86	0.9	0.88	0.91	0.91	-0.85	0.91	-0.86	0.62	0.09

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Current Liab	489.3K	552.3K	2.2M	2.7M	2.5B	2.6B
Total Current Liabilities	489.3K	552.3K	2.3M	2.8M	2.7M	1.7M
Total Stockholder Equity	943.3K	19.7M	71.6M	56.0M	40.9M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	8.8K	21.5K	216.2K	95.7K	280.4K	294.4K
Net Debt	(1.2M)	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(22.8M)
Retained Earnings	(6.8M)	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(52.5M)
Accounts Payable	489.3K	552.3K	2.2M	2.7M	2.5M	1.6M
Cash	1.2M	19.2M	51.5M	37.2M	21.9M	24.1M
Non Current Assets Total	199.8K	122.7K	1.2M	113.6K	306.3K	363.2K
Cash And Short Term Investments	1.2M	19.2M	70.7M	55.2M	41.3M	34.5M
Common Stock Shares Outstanding	6.3M	6.2M	10.9M	10.9M	10.8M	9.4M
Liabilities And Stockholders Equity	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Stockholder Equity	7.7M	32.4M	96.7M	95.7M	96.3M	61.0M
Total Liab	489.3K	660.8K	2.4M	2.8M	2.7M	1.8M
Net Invested Capital	929.3K	19.8M	71.6M	56.0M	40.9M	34.7M
Total Current Assets	1.2M	20.2M	72.7M	58.7M	43.3M	36.1M
Capital Stock	25.4K	622.0	1.1K	1.1K	1.1K	1.0K
Net Working Capital	743.5K	19.7M	70.4M	55.9M	40.7M	34.3M
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Lantern Stock analysis

When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.

	Stocks Directory Find actively traded stocks across global markets
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.47)

Return On Assets

(0.22)

Return On Equity

(0.33)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Net Debt vs Current Deferred Revenue Analysis

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Debt

Current Deferred Revenue

Lantern Pharma fundamental ratios Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lantern Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity